EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-Release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyperparathyroidism Patients

Charles W Bishop, Akhtar Ashfaq, Stephen A Strugnell, John Choe, Nilay Patel, Keith C Norris, Stuart M Sprague

American Journal of Nephrology · 2024

DOI: 10.1159/000541138 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Nephrology, 2024. Verfasst von Charles W Bishop und 6 weiteren Autor:innen. Beteiligte Einrichtung: OPKO Health, Miami, Florida, USA. Hauptthemen laut MEDLINE: Hyperparathyroidism, Secondary, Parathyroid Hormone, Renal Insufficiency, Chronic, Calcifediol. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chronic kidney disease (CKD) drives onerous human and healthcare costs, underscoring an urgent need to avert disease progression. Secondary hyperparathyroidism (SHPT) develops as CKD advances, and persistently elevated parathyroid hormone (PTH) may be nephrotoxic and associated with earlier dialysis onset. This study examines, for the first time, the hypothesis that sustained reduction of elevated intact PTH (iPTH) with extended-release calcifediol (ERC) reduces the nephrotoxic impact of SHPT and forestalls renal decline.

Methods

Changes in estimated glomerular filtration rate (eGFR) were analyzed post hoc in 126 adults with SHPT, stage 3–4 CKD, and low serum 25-hydroxyvitamin D (25D) treated for 1 year with ERC in pivotal trials. ERC was administered at 30 μg/day increasing, as needed, to 60 μg/day to achieve ≥30% reductions in iPTH. Calcium, phosphorus, 25D, 1,25-dihydroxyvitamin D (1,25D), iPTH, eGFR, fibroblast growth factor-23 (FGF23), bone turnover markers (BTMs), and urine albumin-to-creatinine ratio (uACR) were measured at baseline and regular intervals. Participants were categorized by achievement (or not) of sustained ≥30% iPTH reductions over the last 2 quarters of treatment to evaluate differences in eGFR decline.

Results

For all participants, 25D increased 58.5 ± 2.3 (SE) ng/mL (p < 0.001) by the end of treatment (EOT), 1,25D increased 10.1 ± 1.8 pg/mL (p < 0.001), iPTH decreased from 143.8 ± 5.8 pg/mL to 108.8 ± 7.2 (p < 0.001), BTMs improved (p < 0.01), and eGFR declined 2.2 ± 0.5 mL/min/1.73 m2 (p < 0.001). The rate of eGFR decline was >5-fold higher (p = 0.014) in participants who did not achieve sustained iPTH reductions of ≥30% (3.2 ± 0.7; 12.7 ± 2.2%) than in those who did (0.6 ± 0.8; 2.9 ± 2.4%). It was highest in the 30 participants who did not exhibit an iPTH lowering response in both of the last 2 quarters of treatment (5.4 ± 0.9; 20.9 ± 3.4%). Duration of iPTH reduction had no impact on safety parameters. Degree of iPTH reduction at EOT was also associated with slower CKD progression.

Conclusion

Sustained reduction of elevated iPTH with ERC treatment was associated with slower rates of eGFR decline in patients with SHPT and stage 3–4 CKD without raising safety concerns. A prospective trial is warranted to confirm this finding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperparathyroidism, SecondaryParathyroid HormoneRenal Insufficiency, ChronicCalcifediolHumansGlomerular Filtration RateDisease ProgressionFibroblast Growth Factor-23FemaleMaleMiddle AgedVitamin DDelayed-Action PreparationsAgedFibroblast Growth FactorsCalciumPhosphorus

Stichwörter der Autor:innen

Chronic kidney diseaseExtended-release calcifediolParathyroid hormoneProgressionSecondary hyperparathyroidism

Substanzen

Parathyroid HormoneFibroblast Growth Factor-23FGF23 protein, humanVitamin DDelayed-Action PreparationsCalcifediol25-hydroxyvitamin DFibroblast Growth FactorsCalciumPhosphorus

Autor:innen und Institutionen

  • OPKO Health, Miami, Florida, USA.
  • OPKO Health, Miami, Florida, USA, sstrugnell@opko.com.
  • David Geffen School of Medicine, UCLA, Los Angeles, California, USA.
  • NorthShore University Health System-University of Chicago, Pritzker School of Medicine, Evanston, Illinois, USA.

Zitieren

APA

Bishop, C. W., Ashfaq, A., Strugnell, S. A., Choe, J., Patel, N., Norris, K. C., & Sprague, S. M. (2024). Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-Release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyperparathyroidism Patients. American Journal of Nephrology. https://doi.org/10.1159/000541138

Vancouver

Bishop CW, Ashfaq A, Strugnell SA, Choe J, Patel N, Norris KC, et al. Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-Release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyperparathyroidism Patients. American Journal of Nephrology. 2024. doi:10.1159/000541138

BibTeX
@article{Bishop2024,
  author = {Bishop, Charles W and Ashfaq, Akhtar and Strugnell, Stephen A and Choe, John and Patel, Nilay and Norris, Keith C and Sprague, Stuart M},
  title = {Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-Release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyperparathyroidism Patients},
  journal = {American Journal of Nephrology},
  year = {2024},
  doi = {10.1159/000541138}
}
Kostenlos starten →